Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

12 Aug 2022

Abstract excerpt

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological cancers arising from the malignant transformation of mature T cells. In a cohort of 28 PTCL cases, we identified recurrent overexpression of MYCN, a member of the MYC family of oncogenic transcription factors. Approximately half of all PTCL cases was characterized by a MYC expression signature. Inducible expression of MYCN in lymphoid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Lymphoma Diagnosis and Treatment
Share to T-cell and Retrovirus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35960849
DOI: 10.1182/blood.2022016428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphomaPMID 35960849Read ↗

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphomaSemantic proximity Read ↗

Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profilingSemantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphomaSemantic proximity Read ↗

Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?Semantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.Semantic proximity Read ↗

Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.Semantic proximity Read ↗

New insights into the biology of T-cell lymphomasSemantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Novel insights into the pathogenesis of T-cell lymphomasSemantic proximity Read ↗

c-MYC–miRNA circuitrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.